LOGIN  |  REGISTER

Health Catalyst to Participate in Upcoming Investor Conference

December 10, 2024 | Last Trade: US$3.86 0.03 -0.77

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Dan Burton, Chief Executive Officer, Jason Alger, Chief Financial Officer, Dan LeSueur, Chief Operating Officer, and Jack Knight, Vice President of Investor Relations, will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, including a presentation on Wednesday, January 15, 2025, at 10:30 am PT. The webcast link and related presentation materials will be available online at https://ir.healthcatalyst.com.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations and is committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its clients leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Health Catalyst Investor Relations Contact:

Jack Knight
Vice President, Investor Relations
+1 (855) 309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.

Health Catalyst Media Contact:

Amanda Flanders
Senior Vice President, Marketing and Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page